<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169739</url>
  </required_header>
  <id_info>
    <org_study_id>AHA-000-376</org_study_id>
    <nct_id>NCT02169739</nct_id>
  </id_info>
  <brief_title>Remote Preconditioning Over Time To Empower Cerebral Tissue</brief_title>
  <acronym>REM-PROTECT</acronym>
  <official_title>Pilot, Randomized, Controlled, Staggered Start, Feasibility Trial of Ischemic Preconditioning, a Promising Novel Treatment for Stroke Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies in animals and humans has shown that brief periods of reduced blood flow to&#xD;
      one organ or tissue in the body can help protect other tissues from subsequent injury caused&#xD;
      by reduced blood flow such as a stroke. This phenomenon is known as remote ischemic&#xD;
      preconditioning and may help protect brain cells after a stroke. The investigators are&#xD;
      studying a specific stroke type called subcortical stroke that is very common and has a high&#xD;
      rate of recurrent stroke and cognition problems despite intensive prevention measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will enroll 60 patients. All patients will receive best&#xD;
      standard medical therapy for 2 years. In addition, the investigators will randomly assign 40&#xD;
      patients to undergo daily active remote ischemic preconditioning for 1 year, and 20 patients&#xD;
      to 1 year of standard medical therapy followed by 1 year of daily active remote ischemic&#xD;
      preconditioning. Patient structured interviews will be performed to assess if the treatment&#xD;
      is well tolerated and easy for stroke patients to use. Magnetic resonance (MR) pictures of&#xD;
      the brain will be used to determine if the active treatment stops the progression of brain&#xD;
      injury. Cognitive tests and wireless sensor technology measures will used to learn what&#xD;
      happens to the patient's brain and body during the active treatment.&#xD;
&#xD;
      After a subject consents to participate in the study, he/she will first participate in a&#xD;
      study screening phase to ensure a basic level of tolerability of Remote Ischemic Conditioning&#xD;
      (autoRIC™) device. The subject will undergo one full cycle of treatment under observation of&#xD;
      the study team, including 4 cycles of alternating 5 minute inflation and 5 minute off periods&#xD;
&#xD;
      If the subject indicates willingness to continue receiving such treatment (screening&#xD;
      success), she/she will enter the randomized trial phase, and be randomly allocated to the&#xD;
      treatment or control group.&#xD;
&#xD;
      If subject indicates unwillingness to continue receiving such treatment (screening failure),&#xD;
      he/she will not advance to the randomized phase of the trial. Screen failure subjects will be&#xD;
      followed up with a 3-day post-device screening phone call to ensure safety and obtain&#xD;
      information regarding any adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID 19 restrictions&#xD;
  </why_stopped>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Adherence to Ischemic Preconditioning Procedure</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Limb Ischemia as Assessed by the Preconditioning Device</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Self-reported Comfort-discomfort on a Scale of 1-5, With Lowest Score = &quot;Very Comfortable&quot; and 5 = &quot;Very Uncomfortable&quot;</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Cerebral Small Vessel Disease</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Medical therapy only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic Preconditioning + Medical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ischemic Preconditioning</intervention_name>
    <description>Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.</description>
    <arm_group_label>Ischemic Preconditioning + Medical</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I. Clinical&#xD;
&#xD;
          1. Clinical lacunar stroke syndrome within the past 6 months&#xD;
&#xD;
          2. Absence of signs or symptoms of cortical dysfunction&#xD;
&#xD;
          3. No proximal large vessel atherosclerosis, intracranial atherosclerosis or cerebellar&#xD;
             stroke.&#xD;
&#xD;
          4. No major cardioembolic source requiring anticoagulation or other specific therapy&#xD;
&#xD;
        II. Imaging&#xD;
&#xD;
          1. Magnetic Resonance Imaging (MRI) presence of a small subcortical ischemic, any 1 or&#xD;
             more of:&#xD;
&#xD;
               1. Diffusion-weighted imaging (DWI) lesion &lt; 2.0cm in size at largest dimension and&#xD;
                  corresponding to the clinical syndrome.&#xD;
&#xD;
               2. Well delineated focal hyperintensity &lt;2.0 cm in size at largest dimension&#xD;
                  (including rostro-caudal extent) on FLAIR or T2 and clearly corresponding to the&#xD;
                  clinical syndrome. If other focal hyperintensities are present, the case will be&#xD;
                  discussed with the principal investigator prior to randomization&#xD;
&#xD;
               3. Multiple (at least 2) hypointense lesions of size 0.3-1.5 cm at largest dimension&#xD;
                  (including rostro-caudal extent) only in the cerebral hemispheres on FLAIR or T1&#xD;
                  in patients whose qualifying event is clinically hemispheric&#xD;
&#xD;
               4. Well delinated hypointense lesion &lt;1.5 cm in size at the largest dimension&#xD;
                  (including rostro-caudal extent) on FLAIR or T1 corresponding to the clinical&#xD;
                  syndrome. MRI must be done at least 1 months after the qualifying stroke&#xD;
&#xD;
          2. Absence of cortical stroke and large (&gt; 1.5cm) subcortical stroke, recent or remote&#xD;
&#xD;
          3. White matter hyperintensity score of 2 (moderate) or 3 (severe) on the European Scale&#xD;
             of Age-Related White Matter Change&#xD;
&#xD;
          4. Absence of cerebral amyloid antipathy (CAA) as per Boston Criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Disabling stroke (Rankin Scale ≥4)&#xD;
&#xD;
          2. Previous intracranial hemorrhage (excluding traumatic) or hemorrhagic stroke&#xD;
&#xD;
          3. Age under 40 years&#xD;
&#xD;
          4. High risk of bleeding (e.g. recurrent GI or GU bleeding, active peptic ulcer disease,&#xD;
             etc.)&#xD;
&#xD;
          5. Anticipated requirement for long term use of anticoagulants (e.g. recurrent deep&#xD;
             venous thrombosis (DVT)&#xD;
&#xD;
          6. Prior cortical or retinal stroke (diagnosed either clinically or by neuroimaging), or&#xD;
             other prior cortical or retinal transient ischemic attack (TIA)&#xD;
&#xD;
          7. Prior ipsilateral carotid endarterectomy&#xD;
&#xD;
          8. Impaired renal function: estimated GFR &lt;40&#xD;
&#xD;
          9. Intolerance or contraindications to aspirin or clopidogrel (including&#xD;
             thrombocytopenia, prolonged INR)&#xD;
&#xD;
         10. Mini Mental Status Exam score &lt; 24 (adjusted for age and education)&#xD;
&#xD;
         11. Medical contraindication to MRI&#xD;
&#xD;
         12. Pregnancy or women of child-bearing age who are not following an effective method of&#xD;
             contraception&#xD;
&#xD;
         13. Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound&#xD;
             the neurological or functional outcome evaluations&#xD;
&#xD;
         14. SBP &lt;90 or &gt; 200&#xD;
&#xD;
         15. Known history of limb vascular disease, limb vascular bypass surgery, or limb deep&#xD;
             venous thrombosis&#xD;
&#xD;
         16. Prisoners&#xD;
&#xD;
         17. Homeless individuals&#xD;
&#xD;
         18. Patient unable to give informed consent and no available legally authorized&#xD;
             representative to provide informed consent&#xD;
&#xD;
         19. Patient unlikely to be compliant with therapy/ unwilling to return for follow up&#xD;
             visits&#xD;
&#xD;
         20. Concurrent participation in another study with investigational drug or device&#xD;
             treatment&#xD;
&#xD;
         21. Other likely specific cause of stroke (e.g. dissection, vasculitis, prothrombotic&#xD;
             diathesis, drug abuse)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Latisha K Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <results_first_submitted>February 16, 2021</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Latisha Sharma, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ischemic preconditioning</keyword>
  <keyword>remote ischemic preconditioning</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>white matter disease</keyword>
  <keyword>cerebral small vessel disease</keyword>
  <keyword>cognitive decline</keyword>
  <keyword>leukoaraiosis</keyword>
  <keyword>diffusion tensor imaging</keyword>
  <keyword>white matter hyper intensity score</keyword>
  <keyword>European scale of age-related white matter change</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02169739/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medical Therapy Only</title>
          <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Ischemic Preconditioning + Medical</title>
          <description>Treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year, consisting of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients received intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medical Therapy Only</title>
          <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
        </group>
        <group group_id="B2">
          <title>Ischemic Preconditioning + Medical</title>
          <description>Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.&#xD;
Ischemic Preconditioning: Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" lower_limit="73" upper_limit="75"/>
                    <measurement group_id="B2" value="63.7" lower_limit="52" upper_limit="71"/>
                    <measurement group_id="B3" value="67.1" lower_limit="52" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Adherence to Ischemic Preconditioning Procedure</title>
        <time_frame>12 months</time_frame>
        <population>The medical intervention arm did not undergo ischemic preconditioning</population>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Preconditioning + Medical</title>
            <description>Treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year, consisting of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients received intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Adherence to Ischemic Preconditioning Procedure</title>
          <population>The medical intervention arm did not undergo ischemic preconditioning</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Limb Ischemia as Assessed by the Preconditioning Device</title>
        <time_frame>12 months</time_frame>
        <population>Data were not collected since no participants reached the 12-month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy Only</title>
            <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ischemic Preconditioning + Medical</title>
            <description>Treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year, consisting of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients received intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Limb Ischemia as Assessed by the Preconditioning Device</title>
          <population>Data were not collected since no participants reached the 12-month follow-up</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self-reported Comfort-discomfort on a Scale of 1-5, With Lowest Score = &quot;Very Comfortable&quot; and 5 = &quot;Very Uncomfortable&quot;</title>
        <time_frame>12 months</time_frame>
        <population>Data were not collected since no participants reached the 12-month follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Medical Therapy Only</title>
            <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Ischemic Preconditioning + Medical</title>
            <description>Treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year, consisting of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients received intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Self-reported Comfort-discomfort on a Scale of 1-5, With Lowest Score = &quot;Very Comfortable&quot; and 5 = &quot;Very Uncomfortable&quot;</title>
          <population>Data were not collected since no participants reached the 12-month follow-up</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medical Therapy Only</title>
          <description>Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.</description>
        </group>
        <group group_id="E2">
          <title>Ischemic Preconditioning + Medical</title>
          <description>Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.&#xD;
Ischemic Preconditioning: Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We faced recruitment challenges over the course of the study. Many patients declined enrollment due to the 12-month time commitment of the study. We faced tolerability and compliance concerns with the few patients enrolled in the study. Despite our efforts, early termination of the trial led to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Latisha Sharma, MD</name_or_title>
      <organization>University of California Los Angeles</organization>
      <phone>310-794-6379</phone>
      <email>lali@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

